MUMBAI, India, May 29 -- Intellectual Property India has published a patent application (202611053016 A) filed by Mr. Akash Vikal; Mr. Samarendra Singh; Mr. Hasibullah Khairi; Mr. Faisal Sheikh; and Mr. Issac V. Cherian, Moradabad, Uttar Pradesh, on April 25, for 'dual-responsive liposomal drug delivery system for targeted cancer therapy.'
Inventor(s) include Mr. Akash Vikal; Mr. Samarendra Singh; Mr. Hasibullah Khairi; Mr. Faisal Sheikh; and Mr. Issac V. Cherian.
The application for the patent was published on May 29, under issue no. 22/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a dual-responsive liposomal drug delivery system for targeted cancer therapy, comprising a phospholipid bilayer vesicle formed of pH-sensitive dioleoylphosphatidylethanolamine, a reactive oxygen species responsive lipid bearing thioketal or boronic ester linkages, and cholesterol, encapsulating a therapeutic payload such as doxorubicin, a nucleic acid, or an immunomodulator. The vesicle is surface-functionalized with a tumour-targeting ligand selected from a cyclic Arg-Gly-Asp peptide, a monoclonal antibody, or an aptamer, conjugated through carbodiimide or click chemistry. The bilayer remains stable at physiological pH and low reactive oxygen species levels in circulation, but is cooperatively destabilized only upon simultaneous exposure to acidic tumour pH and elevated reactive oxygen species, triggering rapid payload release with high spatial and temporal selectivity. An optional fluorescent dye or gadolinium contrast agent confers theranostic-capability. The invention overcomes premature drug leakage and systemic toxicity of conventional liposomes and is applicable to solid, metastatic, and drug-resistant cancers."
Disclaimer: Curated by HT Syndication.
